PDS Biotech Amends Yorkville Note: 100% of Non-ATM Financing Proceeds Now Go to Debt Repayment
PDSB is trading near its 52-week low of $0.195 (14% above the low).
Summary
PDS Biotech amended its Yorkville promissory note to require 100% of non-ATM financing proceeds to be used for debt repayment, while extending the Nasdaq compliance cure period to 180 days.
Key Events · Financing and Capital Events · PDSB
-
100% Mandatory Redemption on Non-ATM Financing
New Section 1(i) requires 100% of net cash proceeds from any equity or equity-linked financing outside the ATM to be paid to Yorkville within 5 business days of receipt.
-
Nasdaq Cure Period Extended to 180 Days
The cure period for the Nasdaq listing deficiency was extended from 75 days to 180 days, giving PDS Biotech more time to regain the $1.00 minimum bid price compliance.
-
Weekly ATM Proceeds Remittance Required
The company must now deliver weekly remittance notices for ATM net proceeds and pay the applicable portion to Yorkville within 1 business day of each notice.
-
Financing Flexibility Severely Constrained
With $5.6M in cash and a going concern warning, the amendment means any future non-ATM equity raise would provide no working capital — all proceeds would go to debt repayment.
Analysis · PDSB · Life Sciences
PDS Biotech has amended its $6 million promissory note with YA II PN, Ltd. (Yorkville), adding a provision that requires 100% of net cash proceeds from any non-ATM equity or equity-linked financing to be paid to the Holder within five business days. This effectively blocks the company from raising capital through any means other than its existing $50 million ATM program without immediately handing the proceeds to Yorkville. The amendment also extends the Nasdaq listing deficiency cure period from 75 to 180 days, giving the company more time to regain compliance with the $1.00 minimum bid price requirement. Against the backdrop of $5.6 million in cash, a going concern warning, and a 36% workforce reduction announced last week, this amendment signals that PDS Biotech's financing options are now severely constrained — any future equity raise outside the ATM will not provide working capital but will instead go directly to debt repayment.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.8% of the 1706 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.